Evidence map›Paper›PMID 39678619›Full record

ArticleAmerican journal of translational research2024

Predictive and prognostic value of combined detection of sTim-3, PG and PD-L1 in immune checkpoint inhibitor therapy for advanced gastric cancer.

Hanyong Zhang, Yan Jiang, Jia Luo, Qin Tan, Mengchang Xu, Binsheng He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hanyong ZhangHunan Provincial Key Laboratory of The Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Provincial First-Class Applied Discipline (Pharmacy) Changsha 410219, Hunan, China.
Yan JiangSchool of Basic Medicine, Changsha Medical University Changsha 410219, Hunan, China.
Jia LuoFirst Clinical College, Changsha Medical University Changsha 410219, Hunan, China.
Qin TanChongqing Three Gorges University Wanzhou, Chongqing 404199, China.
Mengchang XuHunan Provincial Key Laboratory of The Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Provincial First-Class Applied Discipline (Pharmacy) Changsha 410219, Hunan, China.
Binsheng HeThe Hunan Provincial Key Laboratory of The TCM Agricultural Biogenomics, Changsha Medical University Changsha 410219, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the value of combined detection of T-cell immunoglobulin mucin molecule 3 (sTim-3), pepsinogen (PG) and programmed death receptor 1 (PD-L1) in evaluating treatment efficacy and predicting the prognosis of immunosuppressant therapy in advanced gastric cancer.

methodsA retrospective study was conducted on the data of 90 patients with advanced gastric cancer who were treated at the First Affiliated Hospital of Changsha Medical University from January 2019 to February 2021. Patients were divided into effective and ineffective groups based on treatment response. Logistic regression was used to identify the factors affecting the efficacy of immune checkpoint inhibitors in treating progressive gastric cancer. ROC curves were drawn to assess the predictive value of serum sTim-3, PG, and PD-L1 alone or in combination. Serum levels of sTim-3, PG, PD-L1 were compared between the survival and death groups, and univariate and Cox proportional risk regression analyses were conducted to identify factors affecting prognosis of patients with progressive gastric cancer. Survival curves were plotted using the Kaplan-Meier method, and ROC curves were used to assess the prognostic value of combined and individual testing of sTim-3, PG, and PD-L1.

resultsNo statistically significant difference were observed between the effective and ineffective groups in terms of gender, age, body mass index, smoking history, alcohol consumption history, KPS score, tumor site, presence of ascites, or use of other therapies (all

conclusionsTim-3, PG and PD-L1 have significant clinical value in predicting treatment efficacy and prognosis of advanced gastric cancer patients undergoing immunosuppressive therapy.

Indexed as

Advanced gastric cancerImmunosuppressantpepsinogenprogrammed death receptor 1T cell immunoglobulin mucin molecule 3

Identifiers

PMID39678619
PMCPMC11645554

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.